Tecfidera Better at Preventing Relapses than Aubagio, Real-world Study Suggests

Tecfidera Better at Preventing Relapses than Aubagio, Real-world Study Suggests

Publication date: Apr 11, 2019

This post was originally published on this site Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study. In order to make a direct comparison between the two therapies, researchers analyzed patients with RRMS registered in the Danish Multiple Sclerosis Registry who took Aubagio or Tecfidera from October 2013 to May 2018. Tecfidera was more effective at reducing ARRs, with patients showing an adjusted 42% lower relapse rate compared to Aubagio. Treatment discontinuation due to disease worsening was higher in patients treated with Aubagio (22. 1%) compared to Tecfidera (10. 2%), reflecting the higher relapse activity seen in the Aubagio group. The team concluded that -for patients with RRMS, DMF [Tecfidera] is more effective in preventing relapses. ..compared with TFL [Aubagio]. “

Concepts Keywords
Clinical Trials MRI
Cohort Study Dimethyl fumarate
Danish Relapse
Disability Biology
DMF Spinal muscular atrophy
Fumarate Articles
Incidence Life sciences
MRI Biogen
Multiple Sclerosis Multiple sclerosis
Neurology MS
Placebo Patient ARRs disease
Relapse Treatment disease
TFL ByBiogen oral disease

Semantics

Type Source Name
drug DRUGBANK Nonoxynol-9
gene UNIPROT ZC3H12D
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
gene UNIPROT CYREN
disease DOID relapsing-remitting multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
drug DRUGBANK Antithymocyte immunoglobulin (rabbit)
drug DRUGBANK Teriflunomide
drug DRUGBANK Dimethyl fumarate
gene UNIPROT SLC35G1
disease MESH Relapses

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *